Our novel small-molecule drugs combine targeted and immunotherapeutic mechanisms of action for the treatment of cancer patients with clear unmet medical need and limited treatment options.

HDAC6-selective inhibitors

KA2507, our highly selective HDAC6 inhibitor, is currently under investigation at The University of Texas MD Anderson Cancer Center in a Phase I clinical trial for patients with solid tumors.

Our R&D program is focused on a new generation of brain-penetrant, non-genotoxic molecules targeting glioblastoma and other indications.

Read more

PI3K-selective inhibitors

KA2237, our dual-selective PI3K-p110β/δ inhibitor, has been under investigation in a Phase I clinical trial for patients with B-cell lymphoma. The toxicity profile of KA2237 is favourable. The study is now closed to recruitment.

The Phase I clinical trials has been conducted at The University of Texas MD Anderson Cancer Center, as part of our strategic collaboration.

Learn more

Lead
Design
Lead
Optimization
Pre-clinical
Development

Phase I

Phase II

KA2507 – Oral, HDAC6-selective inhibitor

Phase I Monotherapy

Dose escalation, solid tumors
ClinicalTrials.gov Identifier – NCT03008018

KA2237 – Oral, PI3K-p110β/δ-selective inhibitor

Phase I Monotherapy

Dose escalation, B-cell lymphomas
ClinicalTrials.gov Identifier – NCT02679196

Non-hydroxamate, HDAC6-targeted inhibitors
including brain-penetrant agents

Development candidates in progress

Potential being explored in cancer and other indications